New Partnership to Revolutionize Medical Diagnostics
CardiAI, a prominent biotechnology firm specializing in state-of-the-art diagnostic solutions, has proudly announced a groundbreaking collaboration with Carleton University’s Faculty of Engineering and Design, marking a significant milestone in the advancement of medical diagnostics through the utilization of Electrolyte Gated-FET (EG-FET) biosensor technology.
The partnership between CardiAI and Carleton aims to harness the potential of EG-FET biosensors for detecting critical biomarkers in saliva and whole blood. This joint effort not only promises to revolutionize point-of-care diagnostics but also sets the stage for expanding the technology’s applications to a wider array of health conditions.
“We are excited to embark on this transformative journey with Carleton University,” says Dr. Anmol S. Kapoor, Cardiologist and CEO of CardiAI. “The fusion of CardiAI’s biotechnology expertise and Carleton’s prowess in electronics engineering creates a synergy with immense promise for the future of medical diagnostics.Together, we are dedicated to advancing technology that not only addresses current healthcare challenges but also fosters innovation and improves patient outcomes.”
This strategic alliance comes at a pivotal moment as the global healthcare landscape evolves, emphasizing the importance of accessible and efficient medical testing. The innovative EG-FET biosensor technology is poised to play a crucial role in democratizing healthcare by delivering accurate and rapid diagnostic results, particularly for individuals in remote areas with limited access to major hospitals.
“This collaboration underscores the power of interdisciplinary partnerships in driving scientific progress,” says Dr. Ravi Prakash, Associate Professor in Carleton’s Department of Electronics and head of Carleton’s Organic Sensors and Devices Laboratory.
“Our department is thrilled to contribute to the development of cutting-edge biosensor technology that has the potential to redefine point-of-care diagnostics. By leveraging our research strengths, we aim to make a lasting impact on healthcare accessibility and usher in a new era of medical innovation.”
Partnership’s Key Highlights
Cutting-Edge Biosensor Technology: The collaboration focuses on developing and implementing EG-FET biosensor platforms for detecting NT-proBNP and cardiac troponin biomarkers, promising highly sensitive and specific results to enhance medical diagnostics precision. The partnership aims to extend beyond cardiovascular biomarkers, contributing to the development of novel diagnostic solutions for various health conditions.
Global Impact: The joint research and development endeavors will not only benefit local communities but also have a global reach. By improving medical test accessibility through point-of-care diagnostics, the partnership endeavors to positively impact individuals worldwide, ensuring timely and accurate healthcare solutions.
Integration with BioAro’s BioEMR: To maximize EG-FET biosensor technology’s potential, CardiAI and Carleton University will integrate it with BioAro’s BioEMR – an AI-powered Telemedicine Platform and Electronic Medical Records (EMR) system. This integration aims to create a seamless healthcare ecosystem, facilitating efficient patient management and diagnostic reporting.
Note: Content may be edited for style and length.
